Recent Finacing
Recent Raise
Quark Pharmaceuticals develops siRNA therapeutics; PF-04523655 is in two Phase II trials for wet AMD and DME, QPI-1002 completed Phase I with Phase II planned, R&D in Fremont, Boulder, Ness‑Ziona.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Quark Pharmaceuticals.
